A
Alain Matthey
Researcher at Geneva College
Publications - 19
Citations - 858
Alain Matthey is an academic researcher from Geneva College. The author has contributed to research in topics: Acenocoumarol & Nociception. The author has an hindex of 9, co-authored 18 publications receiving 738 citations. Previous affiliations of Alain Matthey include University of Geneva.
Papers
More filters
Journal ArticleDOI
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
Selidji T Agnandji,Angela Huttner,Madeleine E Zinser,Patricia Njuguna,Christine Dahlke,José Francisco Fernandes,Sabine Yerly,Julie-Anne Dayer,Verena Kraehling,Rahel Kasonta,A.A. Adegnika,Marcus Altfeld,Floriane Auderset,Emmanuel B. Bache,Nadine Biedenkopf,Saskia Borregaard,Jessica S Brosnahan,Rebekah Burrow,Christophe Combescure,Jules Alexandre Desmeules,Markus Eickmann,Sarah Katharina Fehling,Axel Finckh,Ana Rita Gonçalves,Martin P. Grobusch,Jay W. Hooper,Alen Jambrecina,Anita Lumeka Kabwende,Gürkan Kaya,Domtila Kimani,Bertrand Lell,Barbara Lemaître,Ansgar W. Lohse,Marguerite Massinga-Loembe,Alain Matthey,Benjamin Mordmüller,Anne Nolting,Caroline Ogwang,Michael Ramharter,Jonas Schmidt-Chanasit,Stefan Schmiedel,Peter Silvera,Felix R. Stahl,Henry M. Staines,Thomas Strecker,Hans Stubbe,Benjamin Tsofa,Sherif R. Zaki,Patricia E. Fast,Vasee S. Moorthy,Laurent Kaiser,Sanjeev Krishna,Stephan Becker,Marie-Paule Kieny,Philip Bejon,Peter G. Kremsner,Marylyn M. Addo,Claire-Anne Siegrist +57 more
TL;DR: RVSV-ZEBOV was reactogenic but immunogenic after a single dose and warrants further evaluation for safety and efficacy, and glycoprotein-binding antibody titers were sustained through 180 days in all participants.
Journal ArticleDOI
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
Angela Huttner,Julie-Anne Dayer,Sabine Yerly,Christophe Combescure,Floriane Auderset,Jules Alexandre Desmeules,Markus Eickmann,Axel Finckh,Ana Rita Gonçalves,Jay W. Hooper,Gürkan Kaya,Verena Krähling,Steven A. Kwilas,Barbara Lemaître,Alain Matthey,Peter Silvera,Stephan Becker,Patricia E. Fast,Vasee S. Moorthy,Marie Paule Kieny,Laurent Kaiser,Claire-Anne Siegrist +21 more
TL;DR: The first safety and immunogenicity results in volunteers receiving 3 × 10(5) plaque-forming units (pfu) of the recombinant vesicular stomatitis virus-based candidate vaccine expressing the Zaire Ebola virus glycoprotein are reported.
Journal ArticleDOI
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients
Tobias Derfuss,François Curtin,Claudia Guebelin,Claire Bridel,Maria Rasenack,Alain Matthey,Renaud Du Pasquier,Myriam Schluep,Jules Alexandre Desmeules,Alois B. Lang,Hervé Perron,Raphaël Faucard,Hervé Porchet,Hans-Peter Hartung,Ludwig Kappos,Patrice H. Lalive +15 more
TL;DR: The safety, pharmacokinetic profile, and pharmacodynamic responses to GNbAC1 are favourable in MS patients over a six-month treatment period.
Journal ArticleDOI
Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.
Flavia Storelli,Alain Matthey,Sébastien Lenglet,Aurélien Thomas,Jules Alexandre Desmeules,Youssef Daali +5 more
TL;DR: The study suggests that genetic extensive metabolizers may not represent a homogenous population and that available genetic data should be considered when addressing drug–drug interactions in clinical practice.
Journal ArticleDOI
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients — a twelve month follow-up
Tobias Derfuss,François Curtin,Claudia Guebelin,Claire Bridel,Maria Rasenack,Alain Matthey,Renaud Du Pasquier,Myriam Schluep,Jules Alexandre Desmeules,Alois B. Lang,Hervé Perron,Raphaël Faucard,Hervé Porchet,Hans-Peter Hartung,Ludwig Kappos,Patrice H. Lalive,Patrice H. Lalive +16 more
TL;DR: The open-label extension up to 12months of a trial testing GNbAC1 in 10 MS patients at 2 and 6mg/kg was described to assess GNbac1 safety, and other objectives were pharmacokinetic and pharmacodynamic assessments.